Literature DB >> 33900848

Altered adipokines in obese adolescents: a cross-sectional and longitudinal analysis across the spectrum of glycemia.

Risa M Wolf1,2,3, Andrew E Jaffe4,5,6,7,8,9, Susana Rodriguez2,3, Xia Lei2,3,10,11, Dylan C Sarver2,3, Alexander T Straub4,12, G William Wong2,3, Sheela N Magge1.   

Abstract

Obesity and type 2 diabetes are rapidly increasing in the adolescent population. We sought to determine whether adipokines, specifically leptin, C1q/TNF-related proteins 1 (CTRP1) and CTRP9, and the hepatokine fibroblast growth factor 21 (FGF21), are associated with obesity and hyperglycemia in a cohort of lean and obese adolescents, across the spectrum of glycemia. In an observational, longitudinal study of lean and obese adolescents, we measured fasting laboratory tests, oral glucose tolerance tests, and adipokines including leptin, CTRP1, CTRP9, and FGF21. Participants completed baseline and 2-year follow-up study visits and were categorized as lean (LC, lean control; n = 30), obese normoglycemic (ONG; n = 61), and obese hyperglycemic (OHG; n = 31) adolescents at baseline and lean (n = 8), ONG (n = 18), and OHG (n = 4) at follow-up. Groups were compared using ANOVA and regression analysis, and linear mixed effects modeling was used to test for differences in adipokine levels across baseline and follow-up visits. Results showed that at baseline, leptin was higher in all obese groups (P < 0.001) compared with LC. FGF21 was higher in OHG participants compared with LC (P < 0.001) and ONG (P < 0.001) and positively associated with fasting glucose (P < 0.001), fasting insulin (P < 0.001), Homeostasis Model Assessment-Insulin Resistance Index (HOMA-IR; P < 0.001), and hemoglobin A1c (HbA1c; P = 0.01). CTRP1 was higher in OHG compared with ONG (P = 0.03). CTRP9 was not associated with obesity or hyperglycemia in this pediatric cohort. At 2 years, leptin decreased in ONG (P = 0.003) and FGF21 increased in OHG (P = 0.02), relative to lean controls. Altered adipokine levels are associated with the inflammatory milieu in obese youth with and without hyperglycemia. In adolescence, the novel adipokine CTRP1 was elevated with hyperglycemia, whereas CTRP9 was unchanged in this cohort.NEW & NOTEWORTHY Leptin is higher in obese adolescents and FGF21 is higher in obese hyperglycemic adolescents. The novel adipokine CTRP1 is higher in obese hyperglycemic adolescents, whereas CTRP9 was unchanged in this adolescent cohort.

Entities:  

Keywords:  adipokines; adolescents; insulin resistance; obesity; type 2 diabetes

Mesh:

Substances:

Year:  2021        PMID: 33900848      PMCID: PMC8285597          DOI: 10.1152/ajpendo.00626.2020

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   5.900


  59 in total

Review 1.  Adipocytes as regulators of energy balance and glucose homeostasis.

Authors:  Evan D Rosen; Bruce M Spiegelman
Journal:  Nature       Date:  2006-12-14       Impact factor: 49.962

2.  FGF-21 as a novel metabolic regulator.

Authors:  Alexei Kharitonenkov; Tatiyana L Shiyanova; Anja Koester; Amy M Ford; Radmila Micanovic; Elizabeth J Galbreath; George E Sandusky; Lisa J Hammond; Julie S Moyers; Rebecca A Owens; Jesper Gromada; Joseph T Brozinick; Eric D Hawkins; Victor J Wroblewski; De-Shan Li; Farrokh Mehrbod; S Richard Jaskunas; Armen B Shanafelt
Journal:  J Clin Invest       Date:  2005-05-02       Impact factor: 14.808

3.  Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia.

Authors:  C Weyer; T Funahashi; S Tanaka; K Hotta; Y Matsuzawa; R E Pratley; P A Tataranni
Journal:  J Clin Endocrinol Metab       Date:  2001-05       Impact factor: 5.958

Review 4.  Type 2 diabetes in children: clinical aspects and risk factors.

Authors:  Silva Arslanian
Journal:  Horm Res       Date:  2002

5.  Elevated circulating levels of CTRP1, a novel adipokine, in diabetic patients.

Authors:  Yaping Xin; Xiaodong Lyu; Chongxian Wang; Yanqin Fu; Suhe Zhang; Chenguang Tian; Qingju Li; Dongming Zhang
Journal:  Endocr J       Date:  2014-06-24       Impact factor: 2.349

6.  Adiponectin and protection against type 2 diabetes mellitus.

Authors:  Joachim Spranger; Anja Kroke; Matthias Möhlig; Manuela M Bergmann; Michael Ristow; Heiner Boeing; Andreas F H Pfeiffer
Journal:  Lancet       Date:  2003-01-18       Impact factor: 79.321

7.  Positional cloning of the mouse obese gene and its human homologue.

Authors:  Y Zhang; R Proenca; M Maffei; M Barone; L Leopold; J M Friedman
Journal:  Nature       Date:  1994-12-01       Impact factor: 49.962

Review 8.  Adiponectin and Cardiovascular Risk. From Pathophysiology to Clinic: Focus on Children and Adolescents.

Authors:  Antonina Orlando; Elisa Nava; Marco Giussani; Simonetta Genovesi
Journal:  Int J Mol Sci       Date:  2019-06-30       Impact factor: 5.923

9.  Oral disposition index predicts the development of future diabetes above and beyond fasting and 2-h glucose levels.

Authors:  Kristina M Utzschneider; Ronald L Prigeon; Mirjam V Faulenbach; Jenny Tong; Darcy B Carr; Edward J Boyko; Donna L Leonetti; Marguerite J McNeely; Wilfred Y Fujimoto; Steven E Kahn
Journal:  Diabetes Care       Date:  2008-10-28       Impact factor: 19.112

10.  Significant gender difference in serum levels of fibroblast growth factor 21 in Danish children and adolescents.

Authors:  Amalie Bisgaard; Kaspar Sørensen; Trine Holm Johannsen; Jørn Wulff Helge; Anna-Maria Andersson; Anders Juul
Journal:  Int J Pediatr Endocrinol       Date:  2014-05-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.